David E Clark

Outsourcing lead optimisation--the quiet revolution.

Christopher G Newton, D. E. Clark, C. G. Newton, 2004, Drug discovery today.

Outsourcing lead optimization: constant change is here to stay.

David E Clark, 2007, Drug discovery today.

In silico ADMET tools: the dawn of a new generation?

D. E. Clark, David E Clark, 2007, Expert opinion on drug discovery.

Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods.

Emanuela Gancia, D. E. Clark, E. Gancia, 2017, Bioorganic & medicinal chemistry letters.

Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.

Steve Price, D. E. Clark, H. Dyke, 2007, Bioorganic & medicinal chemistry letters.

Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists.

Peter Lockey, D. E. Clark, S. Cramp, 2004, Bioorganic & medicinal chemistry letters.

Progress in computational methods for the prediction of ADMET properties.

D. E. Clark, P. Grootenhuis, Peter D J Grootenhuis, 2002, Current opinion in drug discovery & development.

In Silico Predictions of Blood-Brain Barrier Penetration: Considerations to “Keep in Mind”

D. E. Clark, J. Goodwin, David E Clark, 2005, Journal of Pharmacology and Experimental Therapeutics.